Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Felbinac Trometamol Injection
NCT03235778Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of felbinac in postoperative pain (7 arms), sponsored by Yiling Pharmaceutical. Primary endpoint: Tolerance evaluation index up to 48.5 hours. Started Jul 2017; status: completed.
02
Drugs
felbinac
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03235778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235778.